Agreement - April 14, 2025
OncoZenge in agreement for BupiZenge in the GCC Region
OncoZenge and Avernus Pharma General Trading, a pharma marketing company from the UAE, have signed an exclusive agreement to license BupiZenge for commercialization and distribution in the Gulf Cooperation Council (GCC) region.
Acquisition - April 10, 2025
EQT to sell Karo Healthcare to KKR
EQT and KKR has announced that EQT VIII fund has agreed to sell Karo Healthcare to KKR.
Collaboration - April 8, 2025
Circio initiate collaboration with Entos Pharmaceuticals
Circio Holding (former Targovax) and Entos Pharmaceuticals have announced the initiation of a research collaboration.
Biotech Business - April 1, 2025
FDA removes clinical hold of Oncopeptides’ OPD5
Oncopeptides has announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5.
Agreement - March 28, 2025
OncoZenge in agreement for the commercialization of BupiZenge in Europe
The company has entered into a binding agreement with Molteni Farmaceutici regarding exclusive rights to commercialize BupiZenge in Europe.
Agreement - March 24, 2025
Novo Nordisk gains rights to China-based The United Laboratories’ ‘triple G’ obesity drug
Novo Nordisk and the United Laboratories International Holdings Limited (TUL)'s wholly-owned subsidiary, The United Bio-Technology (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.
